key: cord-0919739-qn2gm0fo authors: Caballero‐Marcos, Aránzazu; Salcedo, Magdalena; Alonso‐Fernández, Roberto; Rodríguez‐Perálvarez, Manuel; Olmedo, María; Graus Morales, Javier; Cuervas‐Mons, Valentín; Cachero, Alba; Loinaz‐Segurola, Carmelo; Iñarrairaegui, Mercedes; Castells, Lluís; Pascual, Sonia; Vinaixa‐Aunés, Carmen; González‐Grande, Rocío; Otero, Alejandra; Tomé, Santiago; Tejedor‐Tejada, Javier; Álamo‐Martínez, José María; González‐Diéguez, Luisa; Nogueras‐Lopez, Flor; Blanco‐Fernández, Gerardo; Muñoz‐Bartolo, Gema; Bustamante, Francisco Javier; Fábrega, Emilio; Romero‐Cristóbal, Mario; Martin‐Mateos, Rosa; Del Rio‐Izquierdo, Julia; Arias‐Milla, Ana; Calatayud, Laura; Marcacuzco‐Quinto, Alberto A.; Fernández‐Alonso, Víctor; Gómez‐Gavara, Concepción; Colmenero, Jordi; Muñoz, Patricia; Pons, José A. title: Changes in humoral immune response after SARS‐CoV‐2 infection in liver transplant recipients compared to immunocompetent patients date: 2021-04-27 journal: Am J Transplant DOI: 10.1111/ajt.16599 sha: c44c613761055377be8bdc77779ff49628693325 doc_id: 919739 cord_uid: qn2gm0fo The protective capacity and duration of humoral immunity after SARS‐CoV‐2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti‐nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID‐19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well‐known prognostic impact in COVID‐19. Paired case–control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID‐19. Liver transplant recipients showed a lower incidence of anti‐nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID‐19. In transplant patients, female gender (OR = 13.49, 95% CI: 2.17–83.8), a longer interval since transplantation (OR = 1.19, 95% CI: 1.03–1.36), and therapy with renin–angiotensin–aldosterone system inhibitors (OR = 7.11, 95% CI: 1.47–34.50) were independently associated with persistence of antibodies beyond 6 months after COVID‐19. Therefore, as compared with immunocompetent patients, liver transplant recipients show a lower prevalence of anti‐SARS‐CoV‐2 antibodies and more pronounced antibody levels decline. Coronavirus disease 2019 continues to raise uncertainties about the medium-and long-term clinical course after disease resolution. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection produces early detectable humoral immune responses in most cases reported to date; however, the duration and protective capacity of the humoral immune response are still unknown. Several studies have shown the appearance of neutralizing and protective anti-SARS-CoV-2 antibodies after infection, which confer protection against reinfection in the following 6 months. 1, 2 Older age and a more severe course of the disease have been associated with a more rapid and intense appearance of antibodies. 3, 4 However, no studies have evaluated the medium-term humoral response and its protective role in liver transplant (LT) recipients. As immunosuppressed patients may show weakened immune response to infections, it is paramount to understand the extent and duration of humoral immunity after COVID-19 resolution to delineate surveillance and vaccination protocols. In this prospective nationwide study, we aimed to analyze the incidence, evolution, and conditioning factors of SARS-CoV-2 humoral response within the first 12 months post-SARS-CoV-2 infection in LT recipients as compared to immunocompetent individuals. We herein present preliminary results at 6 months post-SARS-CoV-2 infection. The protective capacity and duration of humoral immunity after SARS-CoV-2 infection are not yet understood in solid organ transplant recipients. A prospective multicenter study was performed to evaluate the persistence of anti-nucleocapsid IgG antibodies in liver transplant recipients 6 months after coronavirus disease 2019 (COVID-19) resolution. A total of 71 liver transplant recipients were matched with 71 immunocompetent controls by a propensity score including variables with a well-known prognostic impact in COVID-19. Paired case-control serological data were also available in 62 liver transplant patients and 62 controls at month 3 after COVID-19. Liver transplant recipients showed a lower incidence of anti-nucleocapsid IgG antibodies at 3 months (77.4% vs. 100%, p < .001) and at 6 months (63.4% vs. 90.1%, p < .001). Lower levels of antibodies were also observed in liver transplant patients at 3 (p = .001) and 6 months (p < .001) after COVID- 19 death within the first 3 months after SARS-CoV-2 infection, active chemotherapy, previous therapy with immunoglobulins or convalescent plasma transfusions, and lack of willingness or ability to provide informed consent. In the LT group, clinical operational tolerance was an additional exclusion criterion, as LT recipients not receiving immunosuppression could be considered as immunocompetent. Cases and controls were matched by a propensity score analysis in a 1/1 ratio. 6 The propensity score was calculated by multiple logistic regression including variables with a well-known prognostic impact in COVID- 19: age, gender, comorbidities (diabetes, arterial hypertension, and cardiovascular disease), hospital admission, requirement of mechanical ventilation, and admission to the intensive care unit. The nearest neighbor approach was used to match LT patients and immunocompetent controls to ensure that both groups were comparable in terms of clinical characteristics and severity of COVID-19. Continuous variables are reported as mean and standard deviations (SD) or as median and interquartile range, as appropriate. Categorical variables are described as absolute numbers and percentages. To assess factors associated with persistence of antibodies at 6 months post-infection, the X 2 test was used, with the Fisher correction, whenever appropriate. Differences between antibodies levels in both groups were compared by the U Mann-Whitney test. Univariate and multivariate logistic regression analyses were performed to identify the independent predictors of persistence of antibodies beyond 6 months in the transplant group. Enter method was followed, including variables showing a p ≤ .10 in the univariate analysis in the multivariable model. The statistical analyses were performed using the SPSS version 22.0 (IBM Corp). Every hypothesis tested was two-tailed and considered significant at p < .05. The evaluation of SARS-Cov-2 humoral response at 6 months after COVID-19 included a total of 142 patients, with 71 in each study group. No patient was excluded from the study, however, due to logistical difficulties, no serum sample was available in 30 of the 101 LT recipients. LT patients with and without available serum samples were comparable in terms of age distribution, sex, diabetes, hypertension, COVID-19 severity, and hospital admission (Table S1 ). COVID-19 was confirmed in all patients by a RT-PCR assay of nasopharyngeal swab specimens, between March 6, 2020 and April 7, 2020. In 116 cases (58 case-control pairs), serological data were available at both months 3 and 6 post-infection ( Figure 1 ). According to propensity score matching, both groups were comparable in terms of age distribution, sex, comorbidities, COVID-19 severity, and hospital admission (Table S2 ). All patients presented symptomatic COVID-19. The majority of patients were from the Madrid area (n = 43; 42.6%), which was the autonomous region with the highest absolute number of COVID-19 confirmed cases during the first wave in Spain. 5 The mean of participants per center was 4.39 Baseline predictors of anti-SARS-CoV-2 IgG antibodies in LT patients (n = 71) were screened using binary logistic regression analysis ( Interestingly, we failed to link the type of immunosuppressive therapy with the persistence of anti-SARS-CoV-2 IgG antibodies at 6 months post-infection. We report the first longitudinal study analyzing the specific hu- inhibitors. 14 Mycophenolate mofetil has also been associated with a reduction in post-infection antibody production, 15 as well as decreased humoral immune response to the influenza vaccine. [16] [17] [18] Conversely, more intense humoral immune response has been described in older patients, particularly in those with a more severe COVID-19. 10, 19, 20 In our study, LT recipients and immunocompetent Finally, we also found that the interval since LT was another independent predictor of antibody development. As a greater interval Bold values indicate the variables independently associated with antibody persistence at 6 months in the multivariate analysis. a These variables pertain to active immunosuppression therapy at COVID-19 diagnosis. since LT is generally associated with lower immunosuppression load and older age, these results were expected. While SARS-CoV-2 antibodies seem to protect against reinfection, antibody levels following infection generally decline. The kinetics of waning antibodies appear to differ according to the severity of infection. A greater reduction of antibodies has been shown in less severe COVID-19 cases, 24 although in patients with greater severity of the disease and higher antibody levels, these levels will also eventually decline. 4 We observed persistence of anti-nucleocapsid IgG antibodies at 6 months after the onset of symptoms in most patients. Similar findings have recently been described in kidney transplant recipients. 14 Persistence of anti-spike IgG antibodies 6 months after COVID-19 has also been described in other studies, 11 although accompanied by a decline in SARS-CoV-2-specific CD4 + T cells and CD8 + T cells. Other elements of innate or cellular immunity may confer protection to SARS-CoV-2 reinfection despite the absence of measurable antibodies. Interestingly, the incidence of reinfection has been inversely associated with baseline antibody levels, including those below the positive threshold. Our study is not without limitations. The high incidence of post-infection antibodies in both study groups may be conditioned by the high proportion of patients with pneumonia that required hospitalization, which represents a more severe disease to that observed in the general population. This may be explained by the difficulties in accessing PCR diagnosis in the mildest or asymptomatic COVID-19 cases that existed during the first wave in Spain. On the other hand, we are aware that the test we used for the detection of antibodies, which is one of the most widely used, is not factually quantitative, and although it correlates well with the amount of antibodies present in the sample, it is not a titration technique in the strictest sense. Furthermore, the shorter half-life of antibodies targeting nucleocapsid compared with antibodies targeting spike protein 25 could have underestimated the proportion of seropositive patients in our study. Finally, COVID-19 therapies were heterogeneous in our cohort and a potential impact on subsequent humoral response cannot be ruled out. This heterogeneity could be explained by the potential pharmacological interactions of antiviral therapy with immunosuppression; consequently, this type of therapy was generally avoided in LT patients. Furthermore, as interferon beta therapy may lead to acute rejection and immune-mediated complications it was rarely used. However, when we analyzed humoral immune response excluding patients treated with interferon beta, we obtained similar results. Moreover, none of these agents were identified as predictors of antibody persistence in the multivariate analysis. Although caution must be exercised when attempting to generalize our results, this is the first study demonstrating a key aspect of the immune response against SARS-CoV-2 infection that may have implications for the vaccination of LT population. In conclusion, LT patients exhibit a lower persistence of antinucleocapsid IgG antibodies within the first 6 months post-infection and more pronounced antibody levels decline. These results call for the need for specific studies regarding vaccination in solid organ transplant recipients receiving chronic immunosuppression to adapt dosing and surveillance protocols. The authors of this manuscript have no conflicts of interest to disclose as described by the American Journal of Transplantation. Antibody status and incidence of SARS-CoV-2 infection in health care workers Humoral immune response to SARS-CoV-2 in Iceland Profiling early humoral response to diagnose novel coronavirus disease (COVID-19) Loss of anti-SARS-CoV-2 antibodies in mild Covid-19 Epidemiological pattern, incidence, and outcomes of COVID-19 in liver transplant patients Implications of the propensity score matching paradox in pharmacoepidemiology Clinical features of patients infected with 2019 novel coronavirus in Wuhan Performance characteristics of five immunoassays for SARS-CoV-2: a head-to-head benchmark comparison Clinical characteristics of coronavirus disease 2019 in China SARS-CoV-2 infection induces robust, neutralizing antibody responses that are stable for at least three months. medRxiv Immunological memory to SARS-CoV-2 assessed for up to 8 months after infection Convergent antibody responses to SARS-CoV-2 in convalescent individuals Effects of cyclosporin A on humoral immune response and resistance against vesicular stomatitis virus in mice Persistence of SARS-CoV-2 antibodies in kidney transplant recipients Mycophenolate mofetil decreases antibody production after cardiac transplantation Immune response to influenza vaccine in adult liver transplant recipients Efficacy of influenza vaccination in adult liver transplant recipients Response of transplant recipients to influenza vaccination based on type of immunosuppression: a meta-analysis Antigenspecific adaptive immunity to SARS-CoV-2 in acute COVID-19 and associations with age and disease severity Antibody responses to SARS-CoV-2: let's stick to known knowns Protective role of tacrolimus, deleterious role of age and comorbidities in liver transplant recipients with Covid-19: results from the ELITA/ELTR multi-center European study Effect of angiotensinconverting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2 COVID-19 and individual genetic susceptibility/receptivity: Role of ACE1/ACE2 genes, immunity, inflammation and coagulation. Might the double x-chromosome in females be protective against SARS-COV-2 compared to the single x-chromosome in males? Antibody responses to SARS-CoV-2 in patients with COVID-19 Changes in SARS-CoV-2 antibody responses impact the estimates of infections in populationbased seroprevalence studies The data that support the findings of this study are available from the corresponding author upon reasonable request.